Post-Adjustment ChiNext Index Attracts Global Assets with Low Valuation and High Growth Potential
Launched in 2010, the ChiNext Index, comprising 100 growth-oriented and innovative enterprises listed on the ChiNext Board, has undergone 53 revisions, reflecting China's economic transformation. The latest changes will further optimize its structure to emphasize emerging growth sectors –new-generation information technology (34%), new energy vehicle (24%) and healthcare (12%), underscoring its alignment with China's strategic shift toward high-tech innovation.
According to Wind, its constituent companies have posted revenue growth of 9.5% YoY and ROE exceeding 12.5% in Q1 2025, demonstrating resilient profitability and breakthroughs in AI chips, EV batteries, and precision medicine. Valuation metrics reinforced appeal: the index trades at a 31x P/E ratio as of June 10, near the 10th percentile since its listing.
By curbing concentration risks and embedding ESG criteria, the reforms strengthen the index's role in reflecting industrial evolution in China and global investment trends. International participation has surged through cross-border channels like Stock Connect, QFII, and feeder funds listed on foreign exchanges. The E Fund ChiNext ETF (159915), the largest among related ETFs, has consistently been the preferred instrument for international investors seeking exposure to China's tech-driven growth since its inclusion in the ETF Connect program in 2022, Over the past year, the fund has drawn in approximately US$ 2.55 billion, highlighting its appeal as a pivotal option in China's equity ETF market.
About E Fund
Established in 2001, E Fund Management Co., Ltd. ("E Fund") is a leading comprehensive mutual fund manager in China with over RMB 3.5 trillion (USD 497 billion) under management.* It offers investment solutions to onshore and offshore clients, helping clients achieve long-term sustainable investment performances. E Fund's clients include both individuals and institutions, ranging from central banks, sovereign wealth funds, social security funds, pension funds, insurance and reinsurance companies, to corporates and banks. Long-term oriented, it has been focusing on the investment management business since inception and believes in the power of in-depth research and time in investing. It is a pioneer and leading practitioner in responsible investments in China and is widely recognized as one of the most trusted and outstanding Chinese asset managers.
Source: E Fund. AuM includes subsidiaries. Data as of March 31, 2025. FX rate is sourced from PBoC.
View original content to download multimedia:https://www.prnewswire.com/news-releases/post-adjustment-chinext-index-attracts-global-assets-with-low-valuation-and-high-growth-potential-302480959.html
SOURCE E Fund Management
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 hours ago
- Business Upturn
MingZhu Logistics Enters Share Purchase Agreement to Acquire Mingzhuchun
SHENZHEN, July 03, 2025 (GLOBE NEWSWIRE) — MingZhu Logistics Holdings Limited ('MingZhu' or the 'Company') (NASDAQ: YGMZ), an elite provider of logistics and transportation services to businesses, today announced it has entered into a Share Purchase Agreement (the 'SPA') to acquire 100% equity of Shenzhen Mingzhuchun Wine Co., Ltd. ('Mingzhuchun'), which operates its liquor distribution business through its two subsidiaries Xiamen Bainian Qianzhuang Wine Group Co., Ltd. and Ningde Mingfu Wine Co., Ltd. in China. Under the SPA, MingZhu shall acquire 100% of Mingzhuchun in exchange for the issuance of 2,000,000 ordinary shares of Mingzhu upon closing. The shareholder of Mingzhuchun shall receive additional First Earnout Payment of 2,000,000 ordinary shares and Second Earnout Payment of 2,000,000 ordinary shares respectively if the net income of Mingzhuchun is no lower than US$1 million for the fiscal year 2025 and 2026 respectively. The closing of the transaction contemplated by the SPA is subject to the satisfaction of the closing conditions set forth therein. The acquisition aligns with Mingzhu's previously announced strategic plan to expand into China's commercial liquor distribution sector, leveraging synergies with its existing business operations. As part of this initiative, the Company has been exploring partnerships with established liquor and spirits distributors in China to strengthen its nationwide distribution network, pending final agreements. Mingzhuchun specializes in distributing high-quality liquor brewed in Maotai Town, Guizhou—the most renowned production hub for China's iconic baijiu (white liquor). As the national drink of China, baijiu dominates the domestic spirits market and is a staple at celebrations, family gatherings, and business banquets. Maotai Town's liquors, in particular, are celebrated for their exceptional heritage and craftsmanship, making them the gold standard in China's liquor industry. About MingZhu Logistics Holdings Limited (NASDAQ: YGMZ) Established in 2002 and headquartered in Shenzhen, China, MingZhu Logistics Holdings Limited is a 4A-rated professional trucking service provider. Based on the Company's regional logistics terminals in Guangdong Province, MingZhu Logistics Holdings offers tailored solutions to our clients to deliver their goods through our network density and broad geographic coverage across the country by a combination of self-owned fleets tractors and trailers and subcontractors' fleets. For more information, please visit Forward-Looking Statements The statements in this press release regarding the Company's future expectations, plans and prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding plans, goals, objectives, strategies, future events, expected performance, assumptions and any other statements of fact that have not occurred. Any statements that contain the words 'may', 'will', 'want', 'should', 'believe', 'expect', 'anticipate', 'estimate', 'calculate' or similar statements that are not factual in nature are to be considered forward-looking statements. Actual results may differ materially from historical results or from those expressed in these forward-looking statements as a result of a variety of factors. These factors include, but are not limited to, the Company's strategic objectives, the Company's future plans, market demand and user acceptance of the Company's products or services, technological advances, economic trends, the growth of the trucking services market in China, the Company's reputation and brand, the impact of industry competition and bidding, relevant policies and regulations, fluctuations in China's macroeconomic conditions, and the risks and assumptions disclosed in the Company's reports provided to the CSRC (China Security Regulatory Commission). In addition, the following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the outcome of any legal proceedings that have been, or will be, instituted against Mingzhucun or other parties to the SPA following announcement of the SPA and transactions contemplated therein; the ability of MingZhu to meet NASDAQ listing standards following the transaction and in connection with the consummation thereof; the inability to complete the transactions contemplated by the SPA due to the failure to meet any closing conditions to the SPA; risks that the proposed transaction disrupts current plans and operations and the potential difficulties in employee retention as a result of the announcement of the SPA and consummation of the transaction described therein; costs related to the proposed acquisition; changes in applicable laws or regulations; the ability of the post-transaction company to meet its financial and strategic goals, due to, among other things, competition; the ability of the post-transaction company to grow and manage growth profitability, maintain relationships with customers and retain its key employees; the possibility that the post-transaction company may be adversely affected by other economic, business, and/or competitive factors; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the 'SEC') by MingZhu. For these and other related reasons, we advise investors not to place any reliance on these forward-looking statements, and we urge investors to review the Company's relevant SEC filings for additional factors that may affect the Company's future results of operations. The Company undertakes no obligation to publicly revise these forward-looking statements subsequent to the filing of these documents as a result of changes in particular events or circumstances. For further information, please contact. MingZhu Logistics Holdings Limited: Jingwei Zhang Email: [email protected] Phone: +86 186-5937-1270 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Wire
3 hours ago
- Business Wire
Leading Independent Proxy Advisory Firm ISS Joins Glass Lewis in Recommending Shareholders Vote to Keep the Current SINOVAC Board in Place
BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (' SINOVAC ' or the ' Company '), a leading provider of biopharmaceutical products in China, today announced that leading independent proxy advisory firm Institutional Shareholder Services Inc. ('ISS') has joined Glass, Lewis & Co. ('Glass Lewis') in recommending that SINOVAC shareholders vote to KEEP the current SINOVAC Board in place by voting the WHITE proxy card 'AGAINST' the election of the Reconstituted Imposter Former Board Slate at the upcoming Special Meeting of Shareholders (the 'Special Meeting'). The SINOVAC Board issued the following statement in response to ISS' recommendation: 'We are thrilled that independent proxy advisors ISS and Glass Lewis recommended shareholders vote to KEEP SINOVAC's current Board in place and OPPOSE the Reconstituted Imposter Former Board Slate. In making their recommendations, ISS and Glass Lewis both recognized the swift actions the current SINOVAC Board has taken to restore fairness and deliver value to SINOVAC's rightful shareholders, and they have criticized the Imposter Former Board's abject governance failures that robbed value from SINOVAC shareholders during its seven-year 'de facto' tenure. 'The facts speak for themselves: over the past four months, the current SINOVAC Board has demonstrated its commitment to righting the wrongs of the Imposter Former Board. The current Board has declared a US$55.00 per common share special cash dividend and has continued to lay the groundwork for additional distributions, is working with NASDAQ to resume trading, and is launching a formal exploration of a future listing on the Stock Exchange of Hong Kong to promote liquidity and support shareholder value creation. 'In contrast, the Imposter Former Board, in close coordination with SAIF, Advantech/Prime Success ('Advantech/Prime') and Vivo Capital (together, 'the Dissenting Investor Group'), continue to attempt to derail our progress through misleading rhetoric, baseless claims and frivolous legal actions. Their self-serving objective is clear: regain control of SINOVAC and deprive common shareholders of their rightful dividend payments. 'We urge shareholders to follow the recommendations of both leading independent proxy advisory firms by voting AGAINST the election of the Reconstituted Imposter Former Board on the WHITE proxy card.' Highlights from the ISS Report include 1 (emphasis added): SUPERIORITY OF THE CURRENT BOARD '[T]he [current] board appears to be working to pay SVA shareholders their fair share of dividends, and to resume trading of the company's shares, which are the two most pressing issues currently facing SVA shareholders.' DIVIDEND PAYMENTS 'In engagement with ISS, when [the dissident's] nominees who were former board members were asked why they did not pay dividends to SVA shareholders when they were board members, they gave several answers. […] However, neither reason is reflected in the company's statements in its annual report for 2023, in which it states that the company 'has no intention to distribute dividends in the near future.' When the available facts outlined in the sections above are taken into account, it is difficult to rationalize the conduct of the former board with regard to dividend distributions to SVA shareholders. ' 'The former board […] presided over transactions that enabled the payment of billions of dollars in dividends to minority shareholders of SLS, all while it told SVA shareholders that it had no plans to pay dividends to them.' POISON PILL AND NASDAQ TRADING HALT 'It appears that the former board used the poison pill as an entrenchment mechanism. The former board declared that it had been triggered over one year prior, and acted to issue shares accordingly. In doing so, it appears that the former board was using it against shareholders who had cast more votes for their candidates at the 2018 AGM than had been cast for management nominees. In that sense, it appears that the former board was using the pill to overturn the will of a majority of shareholders. ' 'During this contest, the dissident has not provided a convincing explanation for why the former board could not remove the trading halt.' '[…] the more than decade-long record of former board members on the dissident slate paints a picture of a board that adopted and triggered a poison pill to disenfranchise shareholders, which led to the trading halt of the company's shares.' IMPOSTER FORMER BOARD'S SELF-DEALING 'Shareholders can reasonably question whether the former SVA board acted appropriately in its appointment of SLS board members, who presumably approved the sale of nearly 41 percent of the entity at a time when SLS was generating healthy profits.' At the Special Meeting, shareholders will have the chance to send a clear message to the Dissenting Investor Group: SINOVAC will no longer be held captive to their self-dealing. SINOVAC's Board urges shareholders to protect their investment and the future of their Company by voting the WHITE proxy card today 'AGAINST' Proposals 1 and 2 at the Special Meeting. For more details on the misdeeds and shareholder harm caused by the Imposter Former Board and Dissenting Investor Group, visit our website 1 Permission to use quotations was neither sought nor obtained. Expand Your Vote is Important Your vote on or before July 8 will be about the future of SINOVAC, your receipt of your make-whole dividend payments in the near-term, and the long-term value of your investment. We urge you to keep SINOVAC's Board in place and vote on the WHITE proxy card ' AGAINST ' Proposal 1 to remove the current Board and ' AGAINST ' Proposal 2 to appoint the Reconstituted Imposter Former Board Slate. Your vote is critical to ensuring that SINOVAC remains on the path to stability, growth, and value creation for all shareholders. DISCARD any items you received asking you to vote for the Reconstituted Imposter Former Board Slate. If you have already voted for the Reconstituted Imposter Former Board Slate, you can subsequently revoke it by using the WHITE proxy card or WHITE voting instruction form to vote. Only your latest-dated vote will count! The Special Meeting of Shareholders will be held on Wednesday, July 9, 2025, at 8:00 a.m. China Standard Time (Tuesday, July 8, 2025, at 8:00 p.m. Atlantic Standard Time). Valid shareholders of record as of the close of business on May 19, 2025, are entitled to vote at the meeting. If you have any questions about locating your control number or voting your shares, please contact our proxy solicitor, Georgeson LLC, toll free at (844) 568-1506 in the U.S and (646) 543-1968 outside the U.S. or via email at SinovacSpecialMeeting@ About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Important Additional Information and Where to Find It In connection with SINOVAC's Special Meeting, SINOVAC has filed with the U.S. Securities and Exchange Commission ('SEC') and mailed to shareholders of record entitled to vote at the Special Meeting a definitive proxy statement and other documents, including a WHITE proxy card. SHAREHOLDERS ARE ENCOURAGED TO READ THE PROXY STATEMENT AND ALL OTHER RELEVANT DOCUMENTS WHEN FILED WITH THE SEC AND WHEN THEY BECOME AVAILABLE BECAUSE THOSE DOCUMENTS WILL CONTAIN IMPORTANT INFORMATION. Investors and other interested parties will be able to obtain the documents free of charge at the SEC's website, or from SINOVAC at its website: You may also obtain copies of SINOVAC's definitive proxy statement and other documents, free of charge, by contacting SINOVAC's Investor Relations Department at ir@ Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions. Such statements are based upon current expectations and current market and operating conditions and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's or Board's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company and Board do not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.
Business Insider
3 hours ago
- Business Insider
Investor consortium increases offer price for ReNew Energy Global transaction
In a regulatory filing, a consortium of investors including Masdar, CPP Investments, ADIA and CEO Sumant Sinh announced it is prepared to increase its offer price for RNW to $8.00 per share from the prior $7.07 offer. The letter said, 'The consortium is pleased to confirm its continued interest in the transaction and would like to thank you, the rest of the special committee and the management of the company, for your time and continued engagement. The consortium would like to take this opportunity to outline where it stands in its evaluation of the transaction, including with regards to value. Subject to alignment on the points outlined below, the consortium sees a clear path to a mutually agreeable transaction on an expedient timeline. With your support, the consortium has undertaken comprehensive due diligence, underscoring its significant investment of resources in this transaction. Our due diligence investigation has allowed us to assess the performance of the company and its outlook and refine our view on valuation. On that basis, the consortium is prepared to increase its offer price to US$8.00 per share, payable in cash, for the entire issued and to be issued share capital of the company not already owned by the members of the consortium. Our revised proposal would provide the company's shareholders with a 26% premium to the closing share price of $6.34 per share on December 10, 2024 and a 39% premium to the 30-day volume-weighted average price of $5.76 per share. The consortium believes that its revised proposal, which would provide shareholders with immediate liquidity and value certainty not available in public markets, would be in the best interest of the company and its shareholders, and the consortium trusts that it bears evidence of its willingness to take the transaction forward. The revised proposal is based on the information that you have made available to us and reflects the findings of our due diligence. The revised proposal is a final non-binding offer. We have already circulated a draft transaction agreement to the Linklaters team. We look forward to engaging with the special committee on it, in order to finalize it as soon as possible. The consortium's remaining due diligence is purely confirmatory in nature and key pending areas have been outlined to the special committee. The consortium's financial advisors will also reach out separately to highlight the specific remaining confirmatory items. The consortium expects the special committee, its advisors and the company to engage with top shareholders to ensure their support of the transaction. In addition, the consortium expects the special committee, its advisors and the company to deliver hard irrevocable commitments from certain major shareholders and from directors prior to the announcement of any binding transaction. Once transaction documents are in near final form, the consortium will seek internal approvals to be able to sign and expects that these approvals can be obtained within three weeks of the transaction documents being finalised.' Don't Miss TipRanks' Half-Year Sale
